Danielle Antalffy
Stock Analyst at UBS
(3.45)
# 904
Out of 5,163 analysts
203
Total ratings
46.15%
Success rate
4.87%
Average return
Main Sectors:
Stocks Rated by Danielle Antalffy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGHT Sight Sciences | Maintains: Buy | $12 → $11 | $3.67 | +199.73% | 4 | Mar 6, 2026 | |
| RXST RxSight | Maintains: Neutral | $8 → $9 | $7.33 | +22.78% | 5 | Feb 26, 2026 | |
| SYK Stryker | Maintains: Neutral | $386 → $400 | $336.77 | +18.78% | 7 | Feb 24, 2026 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $17 → $22 | $21.59 | +1.90% | 16 | Feb 20, 2026 | |
| ATRC AtriCure | Maintains: Buy | $60 → $55 | $29.85 | +84.29% | 14 | Feb 18, 2026 | |
| BSX Boston Scientific | Maintains: Buy | $140 → $120 | $69.13 | +73.59% | 15 | Feb 5, 2026 | |
| ZBH Zimmer Biomet Holdings | Maintains: Sell | $88 → $86 | $93.20 | -7.73% | 7 | Jan 28, 2026 | |
| EW Edwards Lifesciences | Maintains: Neutral | $92 → $95 | $81.81 | +16.12% | 14 | Jan 12, 2026 | |
| INSP Inspire Medical Systems | Maintains: Neutral | $89 → $91 | $58.62 | +55.24% | 8 | Dec 23, 2025 | |
| GKOS Glaukos | Maintains: Buy | $140 → $145 | $97.02 | +49.45% | 3 | Dec 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $62 | $27.13 | +128.53% | 4 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $102 | $87.14 | +17.05% | 12 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $355 → $400 | $219.84 | +81.95% | 13 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6.5 → $5.85 | $1.46 | +300.68% | 8 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $16 → $16 | $13.54 | +18.17% | 5 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $106 → $95 | $64.24 | +47.88% | 10 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $21 | $17.40 | +20.69% | 7 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $585 → $600 | $472.16 | +27.08% | 3 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $190 → $214 | $241.52 | -11.39% | 6 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $57 | $22.99 | +147.93% | 2 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $146 → $148 | $108.03 | +37.00% | 12 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $2.25 | $3.80 | -40.79% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $975 → $825 | $3.26 | +25,245.62% | 2 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $32.34 | -56.71% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $100 | $79.49 | +25.80% | 2 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $12 | $14.09 | -14.83% | 3 | Mar 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $32.54 | +38.31% | 4 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $270 → $275 | $159.36 | +72.57% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $2.64 | +657.58% | 3 | Nov 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $72 → $42 | $6.06 | +593.07% | 7 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $60 | $5.64 | +963.83% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $0.71 | +2,017.45% | 1 | Sep 1, 2020 |
Sight Sciences
Mar 6, 2026
Maintains: Buy
Price Target: $12 → $11
Current: $3.67
Upside: +199.73%
RxSight
Feb 26, 2026
Maintains: Neutral
Price Target: $8 → $9
Current: $7.33
Upside: +22.78%
Stryker
Feb 24, 2026
Maintains: Neutral
Price Target: $386 → $400
Current: $336.77
Upside: +18.78%
Tandem Diabetes Care
Feb 20, 2026
Maintains: Neutral
Price Target: $17 → $22
Current: $21.59
Upside: +1.90%
AtriCure
Feb 18, 2026
Maintains: Buy
Price Target: $60 → $55
Current: $29.85
Upside: +84.29%
Boston Scientific
Feb 5, 2026
Maintains: Buy
Price Target: $140 → $120
Current: $69.13
Upside: +73.59%
Zimmer Biomet Holdings
Jan 28, 2026
Maintains: Sell
Price Target: $88 → $86
Current: $93.20
Upside: -7.73%
Edwards Lifesciences
Jan 12, 2026
Maintains: Neutral
Price Target: $92 → $95
Current: $81.81
Upside: +16.12%
Inspire Medical Systems
Dec 23, 2025
Maintains: Neutral
Price Target: $89 → $91
Current: $58.62
Upside: +55.24%
Glaukos
Dec 23, 2025
Maintains: Buy
Price Target: $140 → $145
Current: $97.02
Upside: +49.45%
Dec 12, 2025
Initiates: Buy
Price Target: $62
Current: $27.13
Upside: +128.53%
Nov 19, 2025
Maintains: Neutral
Price Target: $95 → $102
Current: $87.14
Upside: +17.05%
Nov 19, 2025
Upgrades: Buy
Price Target: $355 → $400
Current: $219.84
Upside: +81.95%
Nov 7, 2025
Maintains: Neutral
Price Target: $6.5 → $5.85
Current: $1.46
Upside: +300.68%
Nov 6, 2025
Maintains: Neutral
Price Target: $16 → $16
Current: $13.54
Upside: +18.17%
Nov 3, 2025
Maintains: Buy
Price Target: $106 → $95
Current: $64.24
Upside: +47.88%
Oct 31, 2025
Maintains: Neutral
Price Target: $24 → $21
Current: $17.40
Upside: +20.69%
Oct 23, 2025
Maintains: Neutral
Price Target: $585 → $600
Current: $472.16
Upside: +27.08%
Oct 14, 2025
Maintains: Buy
Price Target: $190 → $214
Current: $241.52
Upside: -11.39%
Aug 8, 2025
Maintains: Buy
Price Target: $65 → $57
Current: $22.99
Upside: +147.93%
Jan 23, 2025
Maintains: Buy
Price Target: $146 → $148
Current: $108.03
Upside: +37.00%
Mar 29, 2023
Initiates: Neutral
Price Target: $2.25
Current: $3.80
Upside: -40.79%
May 5, 2022
Maintains: Outperform
Price Target: $975 → $825
Current: $3.26
Upside: +25,245.62%
May 5, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $32.34
Upside: -56.71%
May 2, 2022
Maintains: Outperform
Price Target: $75 → $100
Current: $79.49
Upside: +25.80%
Mar 11, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $14.09
Upside: -14.83%
Feb 25, 2022
Maintains: Outperform
Price Target: $40 → $45
Current: $32.54
Upside: +38.31%
Feb 4, 2022
Maintains: Market Perform
Price Target: $270 → $275
Current: $159.36
Upside: +72.57%
Nov 10, 2021
Maintains: Outperform
Price Target: $26 → $20
Current: $2.64
Upside: +657.58%
Nov 5, 2021
Maintains: Market Perform
Price Target: $72 → $42
Current: $6.06
Upside: +593.07%
Apr 1, 2021
Downgrades: Market Perform
Price Target: $60
Current: $5.64
Upside: +963.83%
Sep 1, 2020
Initiates: Outperform
Price Target: $15
Current: $0.71
Upside: +2,017.45%